Mergers, Product Prices, and Innovation: Evidence from the Pharmaceutical Industry

Abstract

Using novel data from the pharmaceutical industry, we study product prices and innovation around mergers. Exploiting within-deal variation in product market consolidation, we show that prices increase more for drugs in consolidating markets than for matched control drugs. Estimates indicate a 2% average price effect that persists for about one year. Price increases expand with acquirer-target product similarity and are more pronounced within less competitive product markets with fewer players and no generic competition. Examination of trade-offs reveals these deals generate significant shareholder value. They also spur labeling and other manufacturing-related innovation, but not the development of new drugs.